Dare Bioscience Inc reports results for the quarter - Earnings Summary

• Dare Bioscience Inc DARE.OQ reported a quarterly adjusted loss of 55 cents​​ per share for the quarter , higher than the same quarter last year, when the company reported EPS of $-1.08. The mean expectation of four analysts for the quarter was for a loss of 73 cents per share. Wall Street expected results to range from -93 cents to -61 cents per share.

• Reported revenue was zero​; analysts expected $4.05 million.

• Dare Bioscience Inc's reported EPS for the quarter was a loss of 55 cents​.

• The company reported a quarterly loss of $4.68 million.

• Dare Bioscience Inc shares had risen by 10.0% this quarter and lost 3.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Dare Bioscience Inc is 13.00

This summary was machine generated from LSEG data November 15 at 02:04 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)